drugset / Trial / NCT01526512
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the role of low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1500 mg | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg | Oral |